TOGETHER

Vyxeos® Liposomal is the first dual-drug advanced liposomal formulation of daunorubicin and cytarabine1

LONGER

Vyxeos® Liposomal is the first chemotherapy to significantly increase overall median survival vs conventional chemotherapy* in patients with high-risk** AML2

TOGETHER

Vyxeos® Liposomal is the first dual-drug advanced liposomal formulation of daunorubicin and cytarabine1

LONGER

Vyxeos® Liposomal is the first chemotherapy to significantly increase overall median survival vs conventional chemotherapy* in patients with high-risk** AML2

*comparator arm conventional chemotherapy is 7+3 in induction, 5+2 in second induction and consolidation where given
**High-risk AML is defined as therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC)

References

  1. Tolcher AW, Mayer LD. Future Oncol 2018; 14(13): 1317-1332
  2. Lancet JE et alJ Clin Oncol 2018; 36(26): 2684-2692
  3. Vyxeos Liposomal – Summary of Product Characteristics, October 2019

 

ADVERSE EVENTS REPORTING

 

Reporting of side effects: Adverse events should be reported. Healthcare professionals are asked to report any suspected adverse reactions via their national reporting system. Adverse events should also be reported to Jazz Pharmaceuticals by email: AEreporting@jazzpharma.com or by fax to +44 (0) 1865 598765

 

INT-VYX-2000063 | June 2020